<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Intensive Care Med Exp</journal-id><journal-id journal-id-type="iso-abbrev">Intensive Care Med Exp</journal-id><journal-title-group><journal-title>Intensive Care Medicine Experimental</journal-title></journal-title-group><issn pub-type="epub">2197-425X</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4796640</article-id><article-id pub-id-type="publisher-id">959</article-id><article-id pub-id-type="doi">10.1186/2197-425X-3-S1-A819</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Goal-directed therapy in cancer surgery: a randomised and controlled trial (GRICS II)</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Gerent</surname><given-names>A</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Almeida</surname><given-names>JP</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Galas</surname><given-names>F</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Fukushima</surname><given-names>JT</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Osawa</surname><given-names>E</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>C</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Franco</surname><given-names>R</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Sakr</surname><given-names>Y</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Hajjar</surname><given-names>LA</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><label/>Instituto do C&#x000e2;ncer do Estado de S&#x000e3;o Paulo, Anesthesia and Critical Care, S&#x000e3;o Paulo, Brazil </aff><aff id="Aff2"><label/>Friedrich-Schiller University, Jena, Germany </aff></contrib-group><pub-date pub-type="epub"><day>1</day><month>10</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>1</day><month>10</month><year>2015</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2015</year></pub-date><volume>3</volume><issue>Suppl 1</issue><issue-sponsor>The publication charges for this supplement were funded by Intensive Care Medicine Experimental.</issue-sponsor><elocation-id>A819</elocation-id><permissions><copyright-statement>&#x000a9; Gerent et al.; 2015</copyright-statement><license license-type="open-access"><license-p>This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><conference><conf-name>ESICM LIVES 2015</conf-name><conf-loc>Berlin, Germany</conf-loc><conf-date>3-7 October 2015</conf-date><string-conf><uri>http://www.esicm.org/</uri></string-conf></conference><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p>A perioperative hemodynamic goal-directed therapy (GDT) has been advocated in patients undergoing high risk-surgery in order to reduce postoperative complications. Nevertheless, the benefits of GDT in surgical patients are controversial and may lead to an overuse of fluids, inotropic agents and blood transfusion.</p></sec><sec id="Sec2"><title>Objectives</title><p>The aim of this randomized, controlled, single-center trial was to assess the effect of GDT after abdominal oncology surgery on the incidence of major postoperative complications. We also evaluated the requirements of fluid, inotropic agents, blood transfusion and the intensive care unit (ICU) and hospital length of stay between groups.</p></sec><sec id="Sec3"><title>Methods</title><p>We randomly assigned patients admitted to the ICU after major abdominal oncology surgery to receive either GDT protocol or usual care. The GDT protocol involved hemodynamic optimization aimed at a target of a cardiac index &#x0003e;2.5 L/minute/m2 (by minimally invasive cardiac output monitoring) and a mean arterial pressure of 70 mmHg through a three-step approach: fluid therapy of 250 ml albumin 4% in lactated <italic>Ringer&#x000b4;s</italic> solution, dobutamine infusion up to a dose of 20 &#x000b5;g/kg/minute, and red blood cell transfusion to reach a hemoglobin level above 8g/dL. The primary outcome was a 30-day composite endpoint of acute kidney injury, major cardiovascular complications, adult respiratory distress syndrome, septic shock, reoperation and mortality.</p></sec><sec id="Sec4"><title>Results</title><p>Of the 125 enrolled patients, 62 were assigned to GDT-group and 63 to the usual-care group. There was no difference between groups regarding the amount of fluids received during 8 hours (1345 mL [1042-1771] vs. 1100 mL [780-1388], p = 0.151) of intervention and during 24 hours (2021 mL [1527-2844] vs. 2010 mL [1747-2410], p = 0.372). Patients in the GDT-group were more likely to receive dobutamine (37[66.1%] vs. 12 [23.1%],p &#x0003c; 0.0001). At 30 days after randomization, the composite endpoint occurred in 25.8% in the GDT group and in 22.2% in the usual-care group (p = 0.639). There was no significant difference in blood transfusion requirements, in-hospital mortality, duration of organ support, or length of hospital stay.</p></sec><sec id="Sec5"><title>Conclusions</title><p>In surgical critically ill patients admitted to the ICU after major abdominal oncology surgery, a GDT protocol did not reduce the incidence of major postoperative complications at 30 days. Also, the GDT protocol was associated with an overuse of inotropic agents. (ClinicalTrials.gov number, NCT 01946269.)</p></sec><sec id="Sec6"><title>Conflict of interest</title><p>No conflict of interest to disclose</p></sec></body><back><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pearse</surname><given-names>RM</given-names></name><name><surname>Harrison</surname><given-names>DA</given-names></name><name><surname>MacDonald</surname><given-names>N</given-names></name><name><surname>Gillies</surname><given-names>MA</given-names></name><name><surname>Blunt</surname><given-names>M</given-names></name><name><surname>Ackland</surname><given-names>G</given-names></name><name><surname>Grocott</surname><given-names>MP</given-names></name><name><surname>Ahern</surname><given-names>A</given-names></name><name><surname>Griggs</surname><given-names>K</given-names></name><name><surname>Scott</surname><given-names>R</given-names></name><name><surname>Hinds</surname><given-names>C</given-names></name><name><surname>Rowan</surname><given-names>K</given-names></name><collab>OPTIMISE Study Group</collab></person-group><article-title>Effect of a perioperative, cardiac output-guided hemodynamic therapy algorithm on outcomes following major gastrointestinal surgery: a randomized clinical trial and systematic review</article-title><source>JAMA</source><year>2014</year><volume>311</volume><issue>21</issue><fpage>2181</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1001/jama.2014.5305</pub-id><pub-id pub-id-type="pmid">24842135</pub-id></element-citation></ref></ref-list></back></article>